Advertisement
Screener

Achieve Life Sciences, Inc. (ACHV) Deferred Income Tax Expense (Benefit)

1.0 / 5 stars · 8/40 Roast Me

Achieve Life Sciences, Inc. Deferred Income Tax Expense (Benefit)

Achieve Life Sciences, Inc. (ACHV) reported Deferred Income Tax Expense (Benefit) of -$3.05 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.

Discontinued › Cash Flow › Operating Activities

us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2018-03-01

  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for the quarter ending 2017-12-31 was $0.00.
  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for the quarter ending 2017-09-30 was -$2.93M.
  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for the quarter ending 2017-06-30 was $0.00.
  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for the quarter ending 2017-03-31 was -$124.00K.
  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for fiscal 2017 was -$3.05M.
  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for fiscal 2016 was -$504.00K.
  • Achieve Life Sciences, Inc. deferred income tax expense (benefit) for fiscal 2015 was -$407.00K.
Period endDeferred Income Tax Expense (Benefit) 3 monthDeferred Income Tax Expense (Benefit) 3 month as first filedDeferred Income Tax Expense (Benefit) 6 monthDeferred Income Tax Expense (Benefit) 8 monthDeferred Income Tax Expense (Benefit) 9 monthDeferred Income Tax Expense (Benefit) 12 month
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
-$2.93M
derived: sum of 2 quarters · filed 2018-03-01
-$2.93M
derived: sum of 3 quarters · filed 2018-03-01
-$3.05M
10-K · filed 2018-03-01
2017-09-30-$2.93M
10-K · filed 2018-03-01
-$2.93M
10-Q · filed 2017-11-09
-$2.93M
derived: sum of 2 quarters · filed 2018-03-01
-$3.05M
10-Q · filed 2017-11-09
-$3.18M
derived: sum of 4 quarters · filed 2018-03-01
2017-06-30$0.00
derived: 10-K 12 month − 3 quarters · filed 2018-03-01
-$124.00K
derived: sum of 2 quarters · filed 2018-03-01
-$251.00K
derived: sum of 3 quarters · filed 2018-03-01
-$388.00K
derived: sum of 4 quarters · filed 2018-03-01
2017-03-31-$124.00K
10-K · filed 2018-03-01
-$251.00K
derived: sum of 2 quarters · filed 2018-03-01
-$388.00K
derived: sum of 3 quarters · filed 2018-03-01
-$510.00K
derived: sum of 4 quarters · filed 2018-03-01
2016-12-31-$127.00K
10-K · filed 2018-03-01
-$264.00K
derived: sum of 2 quarters · filed 2018-03-01
-$386.00K
derived: sum of 3 quarters · filed 2018-03-01
-$504.00K
10-K · filed 2018-03-01
2016-09-30-$137.00K
10-K · filed 2018-03-01
-$259.00K
derived: sum of 2 quarters · filed 2018-03-01
-$377.00K
10-Q · filed 2017-11-09
2016-06-30-$122.00K
10-K · filed 2018-03-01
-$240.00K
derived: sum of 2 quarters · filed 2018-03-01
2016-03-31-$118.00K
10-K · filed 2018-03-01
2015-12-31-$407.00K
10-K · filed 2018-03-01
-$407.00K
10-K · filed 2018-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92